Emily A. Dolsen

Emily A. Dolsen

Auto-generated profile, based on publicly available information

Emily A. Dolsen

Mental Health Service, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco. San Francisco, CA, USA; Mental Illness Research Education and Clinical Centers, San Francisco Veterans Affairs Health Care System. San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Consulting and Clinical Psychology
Verified
Journal Article
Closed access
AHAllison G. Harvey
Allison G. Harvey
LDLu Dong
Lu Dong
KHKerrie Hein
Kerrie Hein
SYStephanie H. Yu
Stephanie H. Yu
AMArmando J. Martinez
Armando J. Martinez
DBDaniel J. Buysse
Daniel J. Buysse
To determine if the Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) improves functional impairment, psychiatric symptoms, and sleep and circadian functioning. Adults diagnosed with serious mental illness (SMI) and sleep and circadian dysfunction (N = 121) were randomly allocated to TranS-C plus usual care (TranS-C + UC; n = 61; 8 individual weekly sessions) or 6 months of Usual Care followed by Delayed Treatment with TranS-C (UC-DT; n = 60). Schizophrenia (45%) and anxiety disorders (47%) were common. Blind assessments were conducted pre-treatment, post-treatment, and 6 months later (6FU). The latter two were the post-randomization points of interest. The location was Alameda County Behavioral Health Care Services (ACBHCS), a Community Mental Health Center (CMHC) in California. For the primary outcomes, relative to UC-DT, TranS-C + UC was associated with reduction in functional impairment (b = -3.18, p = 0.025, d = -0.58), general psychiatric symptoms (b = -5.88, p = 0.001, d = -0.64), sleep disturbance (b = -5.55, p < .0001, d = -0.96), and sleep-related impairment (b = -9.14, p < .0001, d = -0.81) from pre-treatment to post-treatment. These effects were maintained to 6-month follow-up (6FU; d = -0.42 to -0.82), except functional impairment (d = -0.37). For the secondary outcomes, relative to UC-DT, TranS-C + UC was associated with improvement in sleep efficiency and on the Sleep Health Composite score from pre-treatment to 6FU. TranS-C + UC was also associated with reduced total wake time and wake time variability from pre-treatment to post-treatment, as well as reduced hallucinations and delusions, bedtime variability, and actigraphy measured waking activity count variability from pre-treatment to 6FU. A novel transdiagnostic treatment, delivered within a CMHC setting, improves selected measures of functioning, symptoms of comorbid disorders, and sleep and circadian outcomes. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

23 April 2020 in Psychological Medicine
Verified
Journal Article
Closed access
PDF file
EDEmily A. Dolsen
Emily A. Dolsen
APAric A. Prather
Aric A. Prather
FLFemke Lamers
Femke Lamers
BPBrenda W. J. H. Penninx
Brenda W. J. H. Penninx
MDMichael R. Dolsen
Michael R. Dolsen
Background: Sleep disturbance has been consistently identified as an independent contributor to suicide risk. Inflammation has emerged as a potential mechanism linked to both sleep disturbance and suicide risk. This study tested associations between sleep duration, insomnia, and inflammation on suicidal ideation (SI) and history of a suicide attempt (SA).Methods: Participants included 2329 adults with current or remitted depression and/or anxiety enrolled in the Netherlands Study of Depression and Anxiety. Sleep duration, insomnia, past week SI, and SA were assessed with self-report measures. Plasma levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α were obtained.Results: Short sleep duration (⩽6 h) compared to normal sleep duration (7–9 h) was associated with reporting a prior SA, adjusting for covariates [adjusted odds ratio (AOR) 1.68, 95% CI 1.13–2.51]. A higher likelihood of SI during the past week was observed for participants with long sleep duration (⩾10 h) compared to normal sleep duration (AOR 2.22, 95% CI 1.02–4.82), more insomnia symptoms (AOR 1.44, 95% CI 1.14–1.83), and higher IL-6 (AOR 1.31, 95% CI 1.02–1.68). Mediation analyses indicated that the association between long sleep duration and SI was partially explained by IL-6 (AOR 1.02, 95% CI 1.00–1.05).Conclusions: These findings from a large sample of adults with depression and/or anxiety provide evidence that both short and long sleep duration, insomnia symptoms, and IL-6 are associated with the indicators of suicide risk. Furthermore, the association between long sleep duration and SI may operate through IL-6.

15 September 2022 in Neurobiology of Stress
Verified
Journal Article
Open access
EDEmily A. Dolsen
Emily A. Dolsen
ABAmy L. Byers
Amy L. Byers
AFAnnesa Flentje
Annesa Flentje
JGJoseph L. Goulet
Joseph L. Goulet
GJGuneet K. Jasuja
Guneet K. Jasuja
TNThomas C. Neylan
Thomas C. Neylan
Sleep disturbance has emerged as an independent, mechanistic, and modifiable risk factor for suicide. Sexual and gender minority (SGM) people disproportionately experience sleep disturbance and are at higher risk of death by suicide relative to cisgender and/or heterosexual individuals. The present narrative review evaluates nascent research related to sleep disturbance and suicide-related thoughts and behaviors (STBs) among SGM populations, and discusses how experiences of minority stress may explain heightened risk among SGM people. Although there is a growing understanding of the link between sleep disturbance and STBs, most research has not been conducted in SGM populations or has not examined suicide as an outcome. Research is needed to examine whether and how aspects of sleep disturbances relate to STBs among SGM people in order to better tailor sleep treatments for SGM populations.

23 February 2022 in Journal of Sleep Research
Verified
Journal Article
Open access
PDF file
LSLaura D. Straus
Laura D. Straus
EDEmily A. Dolsen
Emily A. Dolsen
KNKristen Nishimi
Kristen Nishimi
TNThomas C. Neylan
Thomas C. Neylan
AOAoife O’donovan
Aoife O’donovan
Summary: The coronavirus disease 2019 (COVID‐19) pandemic is a global health crisis with the potential to elicit and worsen psychiatric symptoms, particularly post‐traumatic stress disorder (PTSD) symptoms. Identifying modifiable protective factors is critical for preventing and treating PTSD symptoms both during and following the COVID‐19 pandemic. The present study examined associations of self‐reported sleep quality and anticipatory threat appraisals of the pandemic with PTSD symptoms 6 months later in a sample enriched for pre‐pandemic trauma exposure and PTSD. The sample included 590 adults (mean age 38.2 years) who completed a baseline survey in August/September 2020 and follow‐up survey in March/April 2021. The sample was recruited from a pool of participants interested in a prior study about traumatic stress. Participants self‐reported sleep quality and pandemic‐related anticipatory threat appraisals at baseline. PTSD symptoms were assessed at baseline and follow‐up. Baseline sleep quality was associated with PTSD symptoms at follow‐up controlling for baseline PTSD symptoms (B = −2.49, p = 0.001). Perceived anticipatory threat of the pandemic moderated this association such that worse sleep quality was related to more severe PTSD symptoms at follow‐up for participants with higher (B = −4.07, p < 0.001) but not lower (B = −0.43, p = 0.679) anticipatory threat about the COVID‐19 pandemic. These findings suggest that poor sleep quality may enhance vulnerability to later PTSD symptoms during the pandemic, particularly among those individuals who perceived the pandemic as threatening for their future. Treatments that address sleep problems may be beneficial for reducing trauma‐related symptoms during and following the global health crisis.

12 October 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
EDEmily A. Dolsen
Emily A. Dolsen
KNKristen Nishimi
Kristen Nishimi
KLKaja Z. LeWinn
Kaja Z. LeWinn
ABAmy L. Byers
Amy L. Byers
PTPaige Tripp
Paige Tripp
AOAoife O'DOnovan
Aoife O'DOnovan

12 May 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
KNKristen Nishimi
Kristen Nishimi
BBBrian Borsari
Brian Borsari
PTPaige Tripp
Paige Tripp
AJAhmad Jiha
Ahmad Jiha
EDEmily A. Dolsen
Emily A. Dolsen
AOAoife O'DOnovan
Aoife O'DOnovan